University of Sussex

University of Sussex

Name of leader and affiliation
Simon Waddell

The University of Sussex was the first of the new wave of UK universities founded in the 1960s, receiving its Royal Charter in August 1961. Sussex has become a leading teaching and research institution, as reflected in the 2008 Research Assessment Exercise. Over 90 per cent of Sussex research activity was rated as world leading, internationally excellent or internationally recognised, confirming the University among the leading 30 research universities in the UK.

Brighton and Sussex Medical School (BSMS) was established in 2003 as a partnership between the Universities of Brighton and Sussex and as such benefits from the Universities’ distinctive traditions and shared strengths in biomedical sciences and healthcare. Both Universities received grade 5 biomedical research ratings in the most recent Research Assessment Exercise. The Medical School has close collaborative links with the School of Life Sciences (with translational drug discovery and metabolomics groups) and the MRC Genome Damage and Stability Centre at the University of Sussex, and the School of Pharmacy and Biological Sciences at the University of Brighton. As a newly developed research institution, BSMS has first-class research laboratories for both clinical and basic biomedical research. In addition, fostering collaboration between clinical and research bases, the Brighton and Sussex Clinical Investigation and Research Unit (CIRU) offers an expansive resource of expertise and specialised equipment for clinical research.



Sorry, no posts found for this author.

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.